Quest PharmaTech Inc. is a Canada-based company engaged in the discovery, development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions, based on its SonoLight Technology platform. The SonoLight Technology is based on a non-toxic family of photosensitizing and sonosensitizing, small molecular weight compounds called Hypocrellin, isolated from a parasitic fungus that grows on bamboo trees in China. Quest is developing these compounds as drugs, as well as developing means of activating and delivering them to target tissues. The Company’s lead product, SL017, is a topical formulation indicated for dermatology applications. A second product from the SonoLight platform, SL052, is an injectable formulation that has received approval from Health Canada’s Therapeutic Product Division to initiate a Phase I clinical trial for the treatment of prostate cancer.